Equity Research, Broker Reports, and media content on PROBIODRUG AG

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about PROBIODRUG AG
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on PROBIODRUG AG. We currently have 5 research reports from 1 professional analysts.

Date Source Announcement
08Dec16 06:00 GNW Probiodrug: Innovative Phase II study design of Glutaminylcyclase Inhibitor PQ912 in early Alzheimer's disease
16Nov16 06:01 GNW Amyloid-beta (Abeta) aggregate-clearing by the murine anti-pyroglutamate-3 Abeta IgG2a monoclonal antibody PBD-C06 with and without a complement mutation in an Alzheimer's mouse model
10Nov16 06:00 GNW Probiodrug reports Third Quarter 2016 Business Update
03Nov16 06:00 GNW Probiodrug AG to Publish its Third Quarter 2016 Business Update on 10 November 2016
06Oct16 07:59 GNW Probiodrug announces pricing of a EUR 14.9 million accelerated bookbuild offering of new shares
05Oct16 04:47 GNW Probiodrug launches capital increase by means of an accelerated bookbuild offering
13Sep16 06:00 GNW Combination therapy with Glutaminyl Cyclase (QC) inhibitor PQ912 & pGlu-Abeta specific antibody PBD-C06 shows clear additive effects in reducing pGlu-Abeta as well as Abeta in Alzheimer-mouse model
  • Frequency of research reports


  • Research reports on


  • Providers covering


Latest Content

View the latest research, videos, and podcasts for this company.